P.02

Liktor the Paperwork Maniption Apr of 1865, no patrons with require	er to respected to a substantian of Information unitage it distinguise railed DIAS contraction
	15R 37 CFR 3.70(b)
Applicanuparent Owner: CADILA PHARMACEUTICALS LTD	
Application No./Patent No.: 10/565,211	Filed/lesue Date: March 11, 2003
Titled: Process for manufacturing pharmaceutics) composite sithms (obstructive lung discase)	ition comprises of mycobadanum w in the treatment of
CADILA PHARMACEUTICALE LTD: COR	PORATION
	s of pasigness, e.g., desperation, partitionally, but starting, presentation and many, etc.
states that it is:	
1. X the sealgness of the emire right, title, and interest in:	
2. In expignee of tees then the entire right, titin, and interes (The extent (by percentage) of its ownership interest ix:	at ire
3.	complete assignment from the of the joint inventors was made)
the patent application/patent identified above, by virue of either:	
	ellan/patent identified above. The assignment was recorded in 127021 , Frame .0548 , or for which a
D A shale at this term this increased in a star patent and in-	tion/patent identified above, in the current assignee as follows:
1. From:	COMPAGUITE STEERS STEERS IN THE CRITARY SEESURE SE WINNES.
	to Detect and Wandara to Planta
The document was recorded in the United Signal Real	or for which a copy themot is attached.
2. From;	.To:
The document was recorded in the United Sta	1
3. From:	To:
The decument was recorded in the United State	
Ree)Frame	or for which a copy thereof is attached.
Additional documents in the chair of title are listed on a	
As required by S7 CFR 3.73(b)(1)(i), the documentary evider or concurrently is being, submitted for recordation purguent to	nce of the chain of title from the original owner to the assignes was,
	gnment decement(s)) must be aubmitted to Assignment Division in he records of the USRTO: gee MPSP 302.08]
The undereigned (whose fills is supplied below) is authorized to ect of	on bohalf of the mangage.
Chamen B.M	3 Nd Dec. 2010
Signature	
Deltuipah M. KHAMAR	Executive Director
Printed by Typing Name	Title:

on is betwine by 37 CPR 3.78(a). The information is required to chast of really a temperate by the pulsic which is the initial physic electric and considered by the pulsic which is the considered by the U.S. C. 122 and 37 CPR (15 and 71st. The collection is estimated by the 12 initiates to particular planting the completed application from the USPTC. Type will vary be providing upon the individual case. Any mirror articular distriction from the Third Information Office, L.S. Palent and Trainmant Strike and the Palent Information Office, L.S. Palent and Trainmant Strike, the P.P. C. Sen 1446, American V. A. 22313-1462. DO NOT SEND PRES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissions, V.A. 22313-1462.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your-submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Palent and Trademork. Office is by process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (6 U.S.C. 552), and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.

A record from this system of records may be disclosed, as a routine use, in the course of

presenting evidence to a court, magistrate, or equilibrative tribunal, including disclosures to opposing course in the course of softenent negotiations. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the

A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency: having need for the information injuries to bestone a contract. Recibiants of the Agency: having need for the information injuries to be perform a contract. Recibiants of information shall be required to comply with the requirements of the Privacy Act of 1974, as emended, pursuant to 6 U.S.C. 552a(m).

A record related to an international Application filed under the Patent Cooperation Treaty in

this system of records may be displaced, as a routine use, to the international Suresu of the World intellectual Property Organization, pursuant to the Patent Cooperation Tracty.

A record in this system of records may be disclosed, as a routine use, to another federal

agency for purposes of National Security review (35 U.S.D. 181) and for review pursuant to

agency for purposes or resident country seview (or a country seview) the Atomic Energy Act (42 U.S.C. 218(o)).

A report from this system of records may be disclosed, as a routine use, to the Administrator,
General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2908. Such disclosure shall

previous and programs, whose summing or 40 U.S.C. Zelos and Zelos, outer discounts analy be made in accordance with the GSA regulations governing irreportion of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive: Such discipure shall not be used to make determinations about individually.

A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 131. Further, a record may be disclosed, subject to the similations of 37 CEE 4.4. CFR 1.14, as a routing use, to the public if the record was find in an application which became abundance or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.

A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency. If the USPTO becomes aware of a violation or potential violation of law or regulation.